FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3112855498> ?p ?o ?g. }

• W3112855498 abstract "Poly (ADP-ribose)-polymerase inhibitors (PARPi) have been approved for cancer patients with germline BRCA1/2 (gBRCA1/2) mutations, and efforts to expand the utility of PARPi beyond BRCA1/2 are ongoing. In preclinical models of triple-negative breast cancer (TNBC) with intact DNA repair, we have previously shown an induced synthetic lethality with combined EGFR inhibition and PARPi. Here, we report the safety and clinical activity of lapatinib and veliparib in patients with metastatic TNBC.A first-in-human, pilot study of lapatinib and veliparib was conducted in metastatic TNBC (NCT02158507). The primary endpoint was safety and tolerability. Secondary endpoints were objective response rates and pharmacokinetic evaluation. Gene expression analysis of pre-treatment tumor biopsies was performed. Key eligibility included TNBC patients with measurable disease and prior anthracycline-based and taxane chemotherapy. Patients with gBRCA1/2 mutations were excluded.Twenty patients were enrolled, of which 17 were evaluable for response. The median number of prior therapies in the metastatic setting was 1 (range 0-2). Fifty percent of patients were Caucasian, 45% African-American, and 5% Hispanic. Of evaluable patients, 4 demonstrated a partial response and 2 had stable disease. There were no dose-limiting toxicities. Most AEs were limited to grade 1 or 2 and no drug-drug interactions noted. Exploratory gene expression analysis suggested baseline DNA repair pathway score was lower and baseline immunogenicity was higher in the responders compared to non-responders.Lapatinib plus veliparib therapy has a manageable safety profile and promising antitumor activity in advanced TNBC. Further investigation of dual therapy with EGFR inhibition and PARP inhibition is needed.ClinicalTrials.gov , NCT02158507 . Registered on 12 September 2014." @default.
• W3112855498 created "2020-12-21" @default.
• W3112855498 creator A5005062075 @default.
• W3112855498 creator A5012750761 @default.
• W3112855498 creator A5017415232 @default.
• W3112855498 creator A5020394578 @default.
• W3112855498 creator A5022163717 @default.
• W3112855498 creator A5023104005 @default.
• W3112855498 creator A5026681970 @default.
• W3112855498 creator A5027595085 @default.
• W3112855498 creator A5029907587 @default.
• W3112855498 creator A5039952665 @default.
• W3112855498 creator A5051181309 @default.
• W3112855498 creator A5063423721 @default.
• W3112855498 creator A5075553640 @default.
• W3112855498 creator A5085329460 @default.
• W3112855498 date "2021-03-04" @default.
• W3112855498 modified "2023-10-15" @default.
• W3112855498 title "An open-label, pilot study of veliparib and lapatinib in patients with metastatic, triple-negative breast cancer" @default.
• W3112855498 cites W1792807003 @default.
• W3112855498 cites W1907038934 @default.
• W3112855498 cites W1966788277 @default.
• W3112855498 cites W1967488625 @default.
• W3112855498 cites W1967763477 @default.
• W3112855498 cites W1982023838 @default.
• W3112855498 cites W1983660720 @default.
• W3112855498 cites W1991808212 @default.
• W3112855498 cites W1997752329 @default.
• W3112855498 cites W2004439203 @default.
• W3112855498 cites W2017394167 @default.
• W3112855498 cites W2018969644 @default.
• W3112855498 cites W2021364153 @default.
• W3112855498 cites W2022565543 @default.
• W3112855498 cites W2030335946 @default.
• W3112855498 cites W2031126792 @default.
• W3112855498 cites W2047579358 @default.
• W3112855498 cites W2050354630 @default.
• W3112855498 cites W2054062143 @default.
• W3112855498 cites W2061001563 @default.
• W3112855498 cites W2075124520 @default.
• W3112855498 cites W2084060660 @default.
• W3112855498 cites W2093514651 @default.
• W3112855498 cites W2096027508 @default.
• W3112855498 cites W2096283457 @default.
• W3112855498 cites W2098737737 @default.
• W3112855498 cites W2105261759 @default.
• W3112855498 cites W2110444464 @default.
• W3112855498 cites W2110878808 @default.
• W3112855498 cites W2118682535 @default.
• W3112855498 cites W2123621576 @default.
• W3112855498 cites W2136437408 @default.
• W3112855498 cites W2142752401 @default.
• W3112855498 cites W2145553893 @default.
• W3112855498 cites W2160325064 @default.
• W3112855498 cites W2163088994 @default.
• W3112855498 cites W2171208628 @default.
• W3112855498 cites W2171972386 @default.
• W3112855498 cites W2564020005 @default.
• W3112855498 cites W2610599595 @default.
• W3112855498 cites W2737523516 @default.
• W3112855498 cites W2770647635 @default.
• W3112855498 cites W2778977385 @default.
• W3112855498 cites W2801863679 @default.
• W3112855498 cites W2802308079 @default.
• W3112855498 cites W2803619079 @default.
• W3112855498 cites W2942052760 @default.
• W3112855498 cites W2956762470 @default.
• W3112855498 cites W2978653983 @default.
• W3112855498 cites W3081315565 @default.
• W3112855498 cites W3086332450 @default.
• W3112855498 cites W3095107109 @default.
• W3112855498 doi "https://doi.org/10.1186/s13058-021-01408-9" @default.
• W3112855498 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7934554" @default.
• W3112855498 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33663560" @default.
• W3112855498 hasPublicationYear "2021" @default.
• W3112855498 type Work @default.
• W3112855498 sameAs 3112855498 @default.
• W3112855498 citedByCount "17" @default.
• W3112855498 countsByYear W31128554982021 @default.
• W3112855498 countsByYear W31128554982022 @default.
• W3112855498 countsByYear W31128554982023 @default.
• W3112855498 crossrefType "journal-article" @default.
• W3112855498 hasAuthorship W3112855498A5005062075 @default.
• W3112855498 hasAuthorship W3112855498A5012750761 @default.
• W3112855498 hasAuthorship W3112855498A5017415232 @default.
• W3112855498 hasAuthorship W3112855498A5020394578 @default.
• W3112855498 hasAuthorship W3112855498A5022163717 @default.
• W3112855498 hasAuthorship W3112855498A5023104005 @default.
• W3112855498 hasAuthorship W3112855498A5026681970 @default.
• W3112855498 hasAuthorship W3112855498A5027595085 @default.
• W3112855498 hasAuthorship W3112855498A5029907587 @default.
• W3112855498 hasAuthorship W3112855498A5039952665 @default.
• W3112855498 hasAuthorship W3112855498A5051181309 @default.
• W3112855498 hasAuthorship W3112855498A5063423721 @default.
• W3112855498 hasAuthorship W3112855498A5075553640 @default.
• W3112855498 hasAuthorship W3112855498A5085329460 @default.
• W3112855498 hasBestOaLocation W31128554981 @default.
• W3112855498 hasConcept C104317684 @default.
• W3112855498 hasConcept C121608353 @default.
• W3112855498 hasConcept C126322002 @default.

• next